Skip to main content
main-content
Erschienen in:
Buchtitelbild

2018 | OriginalPaper | Buchkapitel

1. Multiple Sklerose und andere autoimmune ZNS-Erkrankungen

verfasst von: Martin Stangel, Christoph Kleinschnitz, Mathias Mäurer, Peter Raab, Kurt-Wolfram Sühs, Corinna Trebst

Erschienen in: Autoimmunerkrankungen in der Neurologie

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Autoimmunerkrankungen des zentralen Nervensystems (ZNS) stellen eines der sich am schnellsten entwickelnden Gebiete in der Neurologie dar. Die Entdeckung neuer Autoantikörper hat zur Beschreibung neuer Krankheitsentitäten und zu einer Diversifizierung geführt, die einerseits eine gute differenzialdiagnostische Abgrenzung erfordert, ebenso wie es zu unterschiedlichen Therapieschemata führt. Aber auch klassische Erkrankungen wie die Multiple Sklerose haben mit der Abgrenzung der Neuromyelitis-Optica-Spektrumerkrankungen neue Impulse erhalten. Parallel dazu gab es eine beeindruckende Entwicklung bei den Immuntherapeutika, sodass für diese Erkrankungen unterschiedlichste Therapieoptionen bestehen.
Literatur
Zurück zum Zitat Alusi SH, Worthington J, Glickman S, Bain PG (2001) A study of tremor in multiple sclerosis. Brain 124:720–730 PubMedCrossRef Alusi SH, Worthington J, Glickman S, Bain PG (2001) A study of tremor in multiple sclerosis. Brain 124:720–730 PubMedCrossRef
Zurück zum Zitat Ascherio A, Munger KL (2016) Epidemiology of multiple sclerosis: from risk factors to prevention – an update. Semin Neurol 36(2):103–114 PubMedCrossRef Ascherio A, Munger KL (2016) Epidemiology of multiple sclerosis: from risk factors to prevention – an update. Semin Neurol 36(2):103–114 PubMedCrossRef
Zurück zum Zitat Capello E, Mancardi GL (2004) Marburg type and Balo’s concentric sclerosis: rare and acute variants of multiple sclerosis. Neurol Sci 25(Suppl 4):361–363 CrossRef Capello E, Mancardi GL (2004) Marburg type and Balo’s concentric sclerosis: rare and acute variants of multiple sclerosis. Neurol Sci 25(Suppl 4):361–363 CrossRef
Zurück zum Zitat Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151 PubMedCrossRef Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151 PubMedCrossRef
Zurück zum Zitat Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438–446 PubMedCrossRef Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438–446 PubMedCrossRef
Zurück zum Zitat Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, and Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–415 CrossRef Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, and Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–415 CrossRef
Zurück zum Zitat Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801 Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801
Zurück zum Zitat Comi G, De SN, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM et al (2012) Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 11 (1): 33–41 PubMedCrossRef Comi G, De SN, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM et al (2012) Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 11 (1): 33–41 PubMedCrossRef
Zurück zum Zitat Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, and Filippi M (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374: 1503–1511 CrossRef Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, and Filippi M (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374: 1503–1511 CrossRef
Zurück zum Zitat Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, and Filippi M (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371: 2085–2092 CrossRef Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, and Filippi M (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371: 2085–2092 CrossRef
Zurück zum Zitat Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med 339:285–291 PubMedCrossRef Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med 339:285–291 PubMedCrossRef
Zurück zum Zitat Dippel FW, Mäurer M, Schinzel S, Müller-Bohn T, Larisch K (2015) Krankenversicherungsdaten bestätigen hohe Prävalenz der Multiplen Sklerose. Akt Neurol 42(4):191–196 CrossRef Dippel FW, Mäurer M, Schinzel S, Müller-Bohn T, Larisch K (2015) Krankenversicherungsdaten bestätigen hohe Prävalenz der Multiplen Sklerose. Akt Neurol 42(4):191–196 CrossRef
Zurück zum Zitat Esposito S, Bonavita S, Sparaco M, Gallo A, Tedeschi G (2017) The role of diet in multiple sclerosis: a review. Nutr Neurosci 24:1–14 Esposito S, Bonavita S, Sparaco M, Gallo A, Tedeschi G (2017) The role of diet in multiple sclerosis: a review. Nutr Neurosci 24:1–14
Zurück zum Zitat Filippi M, Rocca MA, Ciccarelli O et al (2016) MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15:292–303 PubMedPubMedCentralCrossRef Filippi M, Rocca MA, Ciccarelli O et al (2016) MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15:292–303 PubMedPubMedCentralCrossRef
Zurück zum Zitat Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367 (12): 1087–1097 Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367 (12): 1087–1097
Zurück zum Zitat Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S (2005) The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 4:111–121 PubMedCrossRef Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S (2005) The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 4:111–121 PubMedCrossRef
Zurück zum Zitat Garren H, Robinson WH, Krasulova E, Havrdova E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L (2008) Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 63: 611–620 PubMedCrossRef Garren H, Robinson WH, Krasulova E, Havrdova E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L (2008) Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 63: 611–620 PubMedCrossRef
Zurück zum Zitat Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg SP, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362: 416–426 CrossRef Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg SP, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362: 416–426 CrossRef
Zurück zum Zitat Gold R et al (2012) Diagnose und Therapie der Multiplen Sklerose. Leitlinie der Deutschen Gesellschaft für Neurologie, www.​dgn.​org Gold R et al (2012) Diagnose und Therapie der Multiplen Sklerose. Leitlinie der Deutschen Gesellschaft für Neurologie, www.​dgn.​org
Zurück zum Zitat Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367 (12): 1098–1107 CrossRef Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367 (12): 1098–1107 CrossRef
Zurück zum Zitat Hartung HP, Aktas O, Menge T, Kieseier BC (2014) Immune regulation of multiple sclerosis. Handb Clin Neurol 122:3–14 PubMedCrossRef Hartung HP, Aktas O, Menge T, Kieseier BC (2014) Immune regulation of multiple sclerosis. Handb Clin Neurol 122:3–14 PubMedCrossRef
Zurück zum Zitat Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360: 2018–2025 CrossRef Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360: 2018–2025 CrossRef
Zurück zum Zitat Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus Interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376 (3): 221–234 CrossRef Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus Interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376 (3): 221–234 CrossRef
Zurück zum Zitat Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676–688 CrossRef Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676–688 CrossRef
Zurück zum Zitat Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser SL, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH (2009) Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460–471 PubMedCrossRef Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser SL, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH (2009) Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460–471 PubMedCrossRef
Zurück zum Zitat Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2017) What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor. Nervenarzt 88 (12): 1421–1427 PubMedCrossRef Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2017) What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor. Nervenarzt 88 (12): 1421–1427 PubMedCrossRef
Zurück zum Zitat Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2017) What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity. Nervenarzt 88 (12): 1428–1434 PubMedCrossRef Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2017) What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity. Nervenarzt 88 (12): 1428–1434 PubMedCrossRef
Zurück zum Zitat Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2018) What is new in symptomatic MS treatment: Part 3-bladder dysfunction. Nervenarzt 89 (2): 184–192 Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2018) What is new in symptomatic MS treatment: Part 3-bladder dysfunction. Nervenarzt 89 (2): 184–192
Zurück zum Zitat Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2018) New aspects of symptomatic MS treatment: Part 4-sexual dysfunction and eye movement disorders. Nervenarzt 89 (2): 193–197 Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth SG (2018) New aspects of symptomatic MS treatment: Part 4-sexual dysfunction and eye movement disorders. Nervenarzt 89 (2): 193–197
Zurück zum Zitat Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, and Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343: 898–904 Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, and Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343: 898–904
Zurück zum Zitat Jörg S, Grohme DA, Erzler M, Binsfeld M, Haghikia A, Müller DN, Linker RA, Kleinewietfeld M (2016) Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cell Mol Life Sci 73(24):4611–4622 PubMedPubMedCentralCrossRef Jörg S, Grohme DA, Erzler M, Binsfeld M, Haghikia A, Müller DN, Linker RA, Kleinewietfeld M (2016) Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cell Mol Life Sci 73(24):4611–4622 PubMedPubMedCentralCrossRef
Zurück zum Zitat Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, and Miller DH (2010) Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 9: 681–688 PubMedCrossRef Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, and Miller DH (2010) Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 9: 681–688 PubMedCrossRef
Zurück zum Zitat Kappos L, Edan G, Freedman MS, Montalban X, Hartung HP, Hemmer B et al (2016) The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87 (10): 978–987 PubMedPubMedCentralCrossRef Kappos L, Edan G, Freedman MS, Montalban X, Hartung HP, Hemmer B et al (2016) The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87 (10): 978–987 PubMedPubMedCentralCrossRef
Zurück zum Zitat Kappos L, Li D, Calabresi PA, O‘Connor P, Bar-Or A, Barkhof F et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378 (9805): 1779–1787 CrossRef Kappos L, Li D, Calabresi PA, O‘Connor P, Bar-Or A, Barkhof F et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378 (9805): 1779–1787 CrossRef
Zurück zum Zitat Kappos L, Radue EW, O‘Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, and Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401 CrossRef Kappos L, Radue EW, O‘Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, and Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401 CrossRef
Zurück zum Zitat Kleinschnitz C, Meuth SG, Kieseier BC, Wiendl H (2007) Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis. Nervenarzt 78:883–911 PubMedCrossRef Kleinschnitz C, Meuth SG, Kieseier BC, Wiendl H (2007) Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis. Nervenarzt 78:883–911 PubMedCrossRef
Zurück zum Zitat Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H (2016) Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action. Nervenarzt 87 (6): 645–659 PubMedCrossRef Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H (2016) Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action. Nervenarzt 87 (6): 645–659 PubMedCrossRef
Zurück zum Zitat Koch M, Uyttenboogaart M, Polman S, De Keyser J (2008) Seizures in multiple sclerosis. Epilepsia 49:948–953 PubMedCrossRef Koch M, Uyttenboogaart M, Polman S, De Keyser J (2008) Seizures in multiple sclerosis. Epilepsia 49:948–953 PubMedCrossRef
Zurück zum Zitat Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F (2015) [Current aspects of therapy conversion for multiple sclerosis]. Nervenarzt 86 (10): 1236–1247 PubMedCrossRef Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F (2015) [Current aspects of therapy conversion for multiple sclerosis]. Nervenarzt 86 (10): 1236–1247 PubMedCrossRef
Zurück zum Zitat Leake JA, Albani S, Kao AS et al (2004) Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 23:756–764 PubMedCrossRef Leake JA, Albani S, Kao AS et al (2004) Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 23:756–764 PubMedCrossRef
Zurück zum Zitat Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:1–9 CrossRef Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:1–9 CrossRef
Zurück zum Zitat McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87 (2): 117–125 McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87 (2): 117–125
Zurück zum Zitat Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F (2018) ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24 (2): 96–120 PubMedCrossRef Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F (2018) ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24 (2): 96–120 PubMedCrossRef
Zurück zum Zitat Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 (3): 209–220 CrossRef Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 (3): 209–220 CrossRef
Zurück zum Zitat Moore P, Harding KE, Clarkson H, Pickersgill TP, Wardle M, Robertson NP (2013) Demographic and clinical factors associated with changes in employment in multiple sclerosis. Mult Scler 19(12):1647–1654 PubMedCrossRef Moore P, Harding KE, Clarkson H, Pickersgill TP, Wardle M, Robertson NP (2013) Demographic and clinical factors associated with changes in employment in multiple sclerosis. Mult Scler 19(12):1647–1654 PubMedCrossRef
Zurück zum Zitat Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. New Engl J Med 343:938–952 PubMedCrossRef Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. New Engl J Med 343:938–952 PubMedCrossRef
Zurück zum Zitat O’Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP et al (2016) Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology 86 (10): 920–930 PubMedPubMedCentralCrossRef O’Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP et al (2016) Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology 86 (10): 920–930 PubMedPubMedCentralCrossRef
Zurück zum Zitat Pender MP, Burrows SR (2014) Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Transl Immunology 3(10):e27 PubMedPubMedCentralCrossRef Pender MP, Burrows SR (2014) Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Transl Immunology 3(10):e27 PubMedPubMedCentralCrossRef
Zurück zum Zitat Petersen G, Wittmann R, Arndt V, Göpffarth D (2014) Epidemiologie der Multiplen Sklerose in Deutschland. Nervenarzt 85:990–998 PubMedCrossRef Petersen G, Wittmann R, Arndt V, Göpffarth D (2014) Epidemiologie der Multiplen Sklerose in Deutschland. Nervenarzt 85:990–998 PubMedCrossRef
Zurück zum Zitat Pierrot-Deseilligny C, Souberbielle JC (2017) Vitamin D and multiple sclerosis: an update. Mult Scler Relat Disord 14:35–45 PubMedCrossRef Pierrot-Deseilligny C, Souberbielle JC (2017) Vitamin D and multiple sclerosis: an update. Mult Scler Relat Disord 14:35–45 PubMedCrossRef
Zurück zum Zitat Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, and Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910 CrossRef Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, and Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910 CrossRef
Zurück zum Zitat Polman CH, Reingold SC, Banwell B et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the „McDonald Criteria“ Ann Neurol 69:292–302 PubMedPubMedCentralCrossRef Polman CH, Reingold SC, Banwell B et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the „McDonald Criteria“ Ann Neurol 69:292–302 PubMedPubMedCentralCrossRef
Zurück zum Zitat Poser CM, Goutieres F, Carpentier MA, Aicardi J (1986) Schilder’s myelinoclastic diffuse sclerosis. Pediatrics 77:107–112 PubMed Poser CM, Goutieres F, Carpentier MA, Aicardi J (1986) Schilder’s myelinoclastic diffuse sclerosis. Pediatrics 77:107–112 PubMed
Zurück zum Zitat Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691 PubMedCrossRef Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691 PubMedCrossRef
Zurück zum Zitat Rolak LA, Fleming JO (2007) The differential diagnosis of multiple sclerosis. Neurologist 13:57–72 PubMedCrossRef Rolak LA, Fleming JO (2007) The differential diagnosis of multiple sclerosis. Neurologist 13:57–72 PubMedCrossRef
Zurück zum Zitat Rovira A, Wattjes MP, Tintore M et al (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 11:471–482 PubMedCrossRef Rovira A, Wattjes MP, Tintore M et al (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 11:471–482 PubMedCrossRef
Zurück zum Zitat Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923 CrossRef Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923 CrossRef
Zurück zum Zitat Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS et al (2013) Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 12 (8): 756–767 PubMedCrossRef Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS et al (2013) Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 12 (8): 756–767 PubMedCrossRef
Zurück zum Zitat Selter RC, Hemmer B (2013) Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther 2:21–30 PubMedPubMedCentral Selter RC, Hemmer B (2013) Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther 2:21–30 PubMedPubMedCentral
Zurück zum Zitat Seze J de, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, and Vermersch P (2004) Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 10: 596–597 PubMedCrossRef Seze J de, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, and Vermersch P (2004) Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 10: 596–597 PubMedCrossRef
Zurück zum Zitat Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H (2016) Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurol Clin Pract 6 (2): 102–115 Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H (2016) Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurol Clin Pract 6 (2): 102–115
Zurück zum Zitat Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H (2016) Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurol Clin Pract 6 (2): 102–115 Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H (2016) Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurol Clin Pract 6 (2): 102–115
Zurück zum Zitat Seze J de, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, and Vermersch P (2004) Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 10: 596–597 PubMedCrossRef Seze J de, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, and Vermersch P (2004) Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 10: 596–597 PubMedCrossRef
Zurück zum Zitat Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC (2015) Towards the implementation of ‚no evidence of disease activity‘ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord 8 (1): 3–13 CrossRef Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC (2015) Towards the implementation of ‚no evidence of disease activity‘ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord 8 (1): 3–13 CrossRef
Zurück zum Zitat Swingler RJ, Compston DA (1992) The morbidity of multiple sclerosis. Q J Med 83:325–337 PubMed Swingler RJ, Compston DA (1992) The morbidity of multiple sclerosis. Q J Med 83:325–337 PubMed
Zurück zum Zitat Tenembaum S, Chitnis T, Ness J, Hahn JS (2007) Acute disseminated encephalomyelitis. Neurology 68:23–36 CrossRef Tenembaum S, Chitnis T, Ness J, Hahn JS (2007) Acute disseminated encephalomyelitis. Neurology 68:23–36 CrossRef
Zurück zum Zitat Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–73 Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–73
Zurück zum Zitat The optic neuritis study group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727–732 PubMedCentral The optic neuritis study group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727–732 PubMedCentral
Zurück zum Zitat Tranchant C, Bhatia KP, Marsden CD (1995) Movement disorders in multiple sclerosis. Mov Disord 10:418–423 PubMedCrossRef Tranchant C, Bhatia KP, Marsden CD (1995) Movement disorders in multiple sclerosis. Mov Disord 10:418–423 PubMedCrossRef
Zurück zum Zitat Williamson EML, Berger JR (2017) Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics 14 (4): 961–973 PubMedCrossRefPubMedCentral Williamson EML, Berger JR (2017) Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics 14 (4): 961–973 PubMedCrossRefPubMedCentral
Zurück zum Zitat Xia L, Lin S, Wang ZC et al (2009) Tumefactive demyelinating lesions: nine cases and a review of the literature. Neurosurg Rev 32:171–179 PubMedCrossRef Xia L, Lin S, Wang ZC et al (2009) Tumefactive demyelinating lesions: nine cases and a review of the literature. Neurosurg Rev 32:171–179 PubMedCrossRef
Zurück zum Zitat Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S (2015) Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol 28(3):206–219 PubMedCrossRef Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S (2015) Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol 28(3):206–219 PubMedCrossRef
Zurück zum Zitat Zimmermann C, Hohlfeld R (1999) ‘Fatigue’ in multiple sclerosis. Nervenarzt 70:566–574 Zimmermann C, Hohlfeld R (1999) ‘Fatigue’ in multiple sclerosis. Nervenarzt 70:566–574
Zurück zum Zitat Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M et al (2014) Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82(15):1302–1306 PubMedPubMedCentralCrossRef Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M et al (2014) Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82(15):1302–1306 PubMedPubMedCentralCrossRef
Zurück zum Zitat Ayzenberg I, Schollhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O et al (2016) Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol 263(3):575–582 PubMedCrossRef Ayzenberg I, Schollhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O et al (2016) Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol 263(3):575–582 PubMedCrossRef
Zurück zum Zitat Bichuetti DB, Oliveira EM, Boulos FC, Gabbai AA (2012) Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol 69(7):938–939 PubMedCrossRef Bichuetti DB, Oliveira EM, Boulos FC, Gabbai AA (2012) Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol 69(7):938–939 PubMedCrossRef
Zurück zum Zitat Bizzoco E, Lolli F, Repice AM, Hakiki B, Falcini M, Barilaro A et al (2009) Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256(11):1891–1898 PubMedCrossRef Bizzoco E, Lolli F, Repice AM, Hakiki B, Falcini M, Barilaro A et al (2009) Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256(11):1891–1898 PubMedCrossRef
Zurück zum Zitat Chitnis T, Ness J, Krupp L, Waubant E, Hunt T, Olsen CS et al (2016) Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 86(3):245–252 PubMedPubMedCentralCrossRef Chitnis T, Ness J, Krupp L, Waubant E, Hunt T, Olsen CS et al (2016) Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 86(3):245–252 PubMedPubMedCentralCrossRef
Zurück zum Zitat Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S et al (2014) Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 20(11):1533–1540 PubMedCrossRef Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S et al (2014) Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 20(11):1533–1540 PubMedCrossRef
Zurück zum Zitat Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ et al (2014) Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014 71(11):1372–1378 PubMedCrossRef Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ et al (2014) Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014 71(11):1372–1378 PubMedCrossRef
Zurück zum Zitat Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66(9):1128–1133 PubMedCrossRef Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66(9):1128–1133 PubMedCrossRef
Zurück zum Zitat Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14 PubMedPubMedCentralCrossRef Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14 PubMedPubMedCentralCrossRef
Zurück zum Zitat Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ (2016) Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 22(3):329–339 PubMedCrossRef Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ (2016) Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 22(3):329–339 PubMedCrossRef
Zurück zum Zitat Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68(11):1412–1420 PubMedCrossRef Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68(11):1412–1420 PubMedCrossRef
Zurück zum Zitat Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70(9):1110–1117 PubMedCrossRef Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70(9):1110–1117 PubMedCrossRef
Zurück zum Zitat Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH et al (2015) Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72(9):989–995 PubMedCrossRef Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH et al (2015) Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72(9):989–995 PubMedCrossRef
Zurück zum Zitat Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A et al (2015) Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2(6):e163 PubMedPubMedCentralCrossRef Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A et al (2015) Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2(6):e163 PubMedPubMedCentralCrossRef
Zurück zum Zitat Kleiter I, Hellwig K, Berthele A, Kumpfel T, Linker RA, Hartung HP et al (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69(2):239–245 PubMedCrossRef Kleiter I, Hellwig K, Berthele A, Kumpfel T, Linker RA, Hartung HP et al (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69(2):239–245 PubMedCrossRef
Zurück zum Zitat Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B et al (2016) Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79(2):206–216 PubMedCrossRef Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B et al (2016) Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79(2):206–216 PubMedCrossRef
Zurück zum Zitat Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112 PubMedCrossRef Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112 PubMedCrossRef
Zurück zum Zitat Lin J, Xue B, Chen Z, Huang X, Pang W, Quan W et al (2016) Effects of early using azathioprine in the acute phase in neuromyelitis optica spectrum disorder. Int J Neurosci 4:1–8 Lin J, Xue B, Chen Z, Huang X, Pang W, Quan W et al (2016) Effects of early using azathioprine in the acute phase in neuromyelitis optica spectrum disorder. Int J Neurosci 4:1–8
Zurück zum Zitat Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71(3):324–330 PubMedCrossRef Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71(3):324–330 PubMedCrossRef
Zurück zum Zitat Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15):1310–1315 PubMedCrossRef Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15):1310–1315 PubMedCrossRef
Zurück zum Zitat Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF et al (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12(6):554–562 PubMedCrossRef Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF et al (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12(6):554–562 PubMedCrossRef
Zurück zum Zitat Qiu W, Kermode AG, Li R, Dai Y, Wang Y, Wang J et al (2015) Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 22(7):1178–1182 PubMedCrossRef Qiu W, Kermode AG, Li R, Dai Y, Wang Y, Wang J et al (2015) Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 22(7):1178–1182 PubMedCrossRef
Zurück zum Zitat Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stogbauer F et al (2015) Long-term therapy with Interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 72(7):756–763 PubMedCrossRef Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stogbauer F et al (2015) Long-term therapy with Interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 72(7):756–763 PubMedCrossRef
Zurück zum Zitat Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E et al (2016) Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3(5):e257 PubMedPubMedCentralCrossRef Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E et al (2016) Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3(5):e257 PubMedPubMedCentralCrossRef
Zurück zum Zitat Tenembaum S, Chitnis T, Nakashima I, Collongues N, McKeon A, Levy M et al (2016) Neuromyelitis optica spectrum disorders in children and adolescents. Neurology 87(9 Suppl 2): 59–66 PubMedCrossRef Tenembaum S, Chitnis T, Nakashima I, Collongues N, McKeon A, Levy M et al (2016) Neuromyelitis optica spectrum disorders in children and adolescents. Neurology 87(9 Suppl 2): 59–66 PubMedCrossRef
Zurück zum Zitat Trebst C, Berthele A, Jarius S, Kumpfel T, Schippling S, Wildemann B et al (2011a) Diagnosis and treatment of neuromyelitis optica : consensus recommendations of the neuromyelitis optica study group. Nervenarzt 82:768–777 PubMedCrossRef Trebst C, Berthele A, Jarius S, Kumpfel T, Schippling S, Wildemann B et al (2011a) Diagnosis and treatment of neuromyelitis optica : consensus recommendations of the neuromyelitis optica study group. Nervenarzt 82:768–777 PubMedCrossRef
Zurück zum Zitat Trebst C, Raab P, Voss EV, Rommer P, Abu-Mugheisib M, Zettl UK et al (2011b) Longitudinal extensive transverse myelitis – it’s not all neuromyelitis optica. Nat Rev Neurol 7(12):688–698 PubMedCrossRef Trebst C, Raab P, Voss EV, Rommer P, Abu-Mugheisib M, Zettl UK et al (2011b) Longitudinal extensive transverse myelitis – it’s not all neuromyelitis optica. Nat Rev Neurol 7(12):688–698 PubMedCrossRef
Zurück zum Zitat Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1):1–16 PubMedCrossRef Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1):1–16 PubMedCrossRef
Zurück zum Zitat Wandinger KP, Stangel M, Witte T, Venables P, Charles P, Jarius S et al (2010) Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren’s syndrome. Arthritis Rheum 62(4):1198–2000 PubMedCrossRef Wandinger KP, Stangel M, Witte T, Venables P, Charles P, Jarius S et al (2010) Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren’s syndrome. Arthritis Rheum 62(4):1198–2000 PubMedCrossRef
Zurück zum Zitat Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46(6):878–886 PubMedCrossRef Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46(6):878–886 PubMedCrossRef
Zurück zum Zitat Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189 PubMedPubMedCentralCrossRef Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189 PubMedPubMedCentralCrossRef
Zurück zum Zitat Wingerchuk DM (2007) Diagnosis and treatment of neuromyelitis optica. Neurologist 13(1):2–11 PubMedCrossRef Wingerchuk DM (2007) Diagnosis and treatment of neuromyelitis optica. Neurologist 13(1):2–11 PubMedCrossRef
Zurück zum Zitat Wingerchuk DM, Weinshenker BG (2008) Neuromyelitis optica. Curr Treat Options Neurol 10(1):55–66 PubMedCrossRef Wingerchuk DM, Weinshenker BG (2008) Neuromyelitis optica. Curr Treat Options Neurol 10(1):55–66 PubMedCrossRef
Zurück zum Zitat Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M et al (2013) Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med 52(9):969–972 PubMedCrossRef Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M et al (2013) Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med 52(9):969–972 PubMedCrossRef
Zurück zum Zitat Armangue T, Leypoldt F, Malaga I, Raspall-Chaure M, Marti I, Nichter C et al (2014) Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 75:317–323 PubMedPubMedCentralCrossRef Armangue T, Leypoldt F, Malaga I, Raspall-Chaure M, Marti I, Nichter C et al (2014) Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 75:317–323 PubMedPubMedCentralCrossRef
Zurück zum Zitat Bauer J, Elger CE, Hans VH, Schramm J, Urbach H, Lassmann H, Bien CG (2007) Astrocytes are a specific immunological target in Rasmussen’s encephalitis. Ann Neurol 62(1):67–80 PubMedCrossRef Bauer J, Elger CE, Hans VH, Schramm J, Urbach H, Lassmann H, Bien CG (2007) Astrocytes are a specific immunological target in Rasmussen’s encephalitis. Ann Neurol 62(1):67–80 PubMedCrossRef
Zurück zum Zitat Bien CG, Schulze-Bonhage A, Deckert M, Urbach H, Helmstaedter C, Grunwald T, Schaller C, Elger CE (2000) Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology 55(12):1823–1828 PubMedCrossRef Bien CG, Schulze-Bonhage A, Deckert M, Urbach H, Helmstaedter C, Grunwald T, Schaller C, Elger CE (2000) Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology 55(12):1823–1828 PubMedCrossRef
Zurück zum Zitat Bien CG, Gleissner U, Sassen R, Widman G, Urbach H, Elger CE (2004) An open study of tacrolimus therapy in Rasmussen encephalitis. Neurology 62(11):2106–2109 PubMedCrossRef Bien CG, Gleissner U, Sassen R, Widman G, Urbach H, Elger CE (2004) An open study of tacrolimus therapy in Rasmussen encephalitis. Neurology 62(11):2106–2109 PubMedCrossRef
Zurück zum Zitat Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M, Lassmann H, Mantegazza R, Villemure JG, Spreafico R, Elger CE (2005) Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 128(Pt 3):454–471 PubMedCrossRef Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M, Lassmann H, Mantegazza R, Villemure JG, Spreafico R, Elger CE (2005) Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 128(Pt 3):454–471 PubMedCrossRef
Zurück zum Zitat Brierley JB, Corsellis JAN, Hierons R, Nevin S (1960) Subacute encephalitis of later adult life mainly affecting the limbic areas. Brain 83:357–368 CrossRef Brierley JB, Corsellis JAN, Hierons R, Nevin S (1960) Subacute encephalitis of later adult life mainly affecting the limbic areas. Brain 83:357–368 CrossRef
Zurück zum Zitat Buckley C, Oger J, Clover L, Tüzün E, Carpenter K, Jackson M, Vincent A (2001) Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50(1):73–78 PubMedCrossRef Buckley C, Oger J, Clover L, Tüzün E, Carpenter K, Jackson M, Vincent A (2001) Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50(1):73–78 PubMedCrossRef
Zurück zum Zitat Chinchilla D, Dulac O, Robain O, Plouin P, Ponsot G, Pinel JF, Graber D (1994) Reappraisal of Rasmussen’s syndrome with special emphasis on treatment with high doses of steroids. J Neurol Neurosurg Psychiatry 57(11):1325–1333 PubMedPubMedCentralCrossRef Chinchilla D, Dulac O, Robain O, Plouin P, Ponsot G, Pinel JF, Graber D (1994) Reappraisal of Rasmussen’s syndrome with special emphasis on treatment with high doses of steroids. J Neurol Neurosurg Psychiatry 57(11):1325–1333 PubMedPubMedCentralCrossRef
Zurück zum Zitat Corsellis JA, Goldberg GJ, Norton AR (1968) „Limbic encephalitis“ and its association with carcinoma. Brain 91(3):481–496 PubMedCrossRef Corsellis JA, Goldberg GJ, Norton AR (1968) „Limbic encephalitis“ and its association with carcinoma. Brain 91(3):481–496 PubMedCrossRef
Zurück zum Zitat Dalmau J (2008) Limbic encephalitis and variants related to neuronal cell membrane autoantigens. Rinsho Shinkeigaku 48(11):871–874 PubMedCrossRef Dalmau J (2008) Limbic encephalitis and variants related to neuronal cell membrane autoantigens. Rinsho Shinkeigaku 48(11):871–874 PubMedCrossRef
Zurück zum Zitat Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098 PubMedPubMedCentralCrossRef Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098 PubMedPubMedCentralCrossRef
Zurück zum Zitat Dogan OM, Deuretzbacher D, Haensch CA, Hagedorn HJ, Halve S, Isenmann S et al (2015) Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry 86:965–972 CrossRef Dogan OM, Deuretzbacher D, Haensch CA, Hagedorn HJ, Halve S, Isenmann S et al (2015) Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry 86:965–972 CrossRef
Zurück zum Zitat Gold M, Pul R, Bach JP, Stangel M, Dodel R (2012) Pathogenic and physiological autoantibodies in the central nervous system. Immunol Rev 248:68–86 PubMedCrossRef Gold M, Pul R, Bach JP, Stangel M, Dodel R (2012) Pathogenic and physiological autoantibodies in the central nervous system. Immunol Rev 248:68–86 PubMedCrossRef
Zurück zum Zitat Granata T, Fusco L, Gobbi G, Freri E, Ragona F, Broggi G, Mantegazza R, Giordano L, Villani F, Capovilla G, Vigevano F, Bernardina BD, Spreafico R, Antozzi C (2003a) Experience with immunomodulatory treatments in Rasmussen’s encephalitis. Neurology 61(12):1807–1810 PubMedCrossRef Granata T, Fusco L, Gobbi G, Freri E, Ragona F, Broggi G, Mantegazza R, Giordano L, Villani F, Capovilla G, Vigevano F, Bernardina BD, Spreafico R, Antozzi C (2003a) Experience with immunomodulatory treatments in Rasmussen’s encephalitis. Neurology 61(12):1807–1810 PubMedCrossRef
Zurück zum Zitat Granata T, Gobbi G, Spreafico R, Vigevano F, Capovilla G, Ragona F, Freri E, Chiapparini L, Bernasconi P, Giordano L, Bertani G, Casazza M, Dalla Bernardina B, Fusco L (2003b) Rasmussen’s encephalitis: early characteristics allow diagnosis. Neurology 60(3):422–425 PubMedCrossRef Granata T, Gobbi G, Spreafico R, Vigevano F, Capovilla G, Ragona F, Freri E, Chiapparini L, Bernasconi P, Giordano L, Bertani G, Casazza M, Dalla Bernardina B, Fusco L (2003b) Rasmussen’s encephalitis: early characteristics allow diagnosis. Neurology 60(3):422–425 PubMedCrossRef
Zurück zum Zitat Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D et al (2010) Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 10:835–844 PubMedCrossRef Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D et al (2010) Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 10:835–844 PubMedCrossRef
Zurück zum Zitat Graus F, Saiz A, Lai M, Bruna J, López F, Sabater L, Blanco Y, Rey MJ, Ribalta T, Dalmau J (2008) Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology 71(12):930–936 PubMedPubMedCentralCrossRef Graus F, Saiz A, Lai M, Bruna J, López F, Sabater L, Blanco Y, Rey MJ, Ribalta T, Dalmau J (2008) Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology 71(12):930–936 PubMedPubMedCentralCrossRef
Zurück zum Zitat Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404 PubMedPubMedCentralCrossRef Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404 PubMedPubMedCentralCrossRef
Zurück zum Zitat Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123(Pt 7):1481–1494 PubMedCrossRef Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123(Pt 7):1481–1494 PubMedCrossRef
Zurück zum Zitat Hart YM, Cortez M, Andermann F, Hwang P, Fish DR, Dulac O, Silver K, Fejerman N, Cross H, Sherwin A et al (1994) Medical treatment of Rasmussen’s syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 44(6):1030–1036 PubMedCrossRef Hart YM, Cortez M, Andermann F, Hwang P, Fish DR, Dulac O, Silver K, Fejerman N, Cross H, Sherwin A et al (1994) Medical treatment of Rasmussen’s syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 44(6):1030–1036 PubMedCrossRef
Zurück zum Zitat Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133(9):2734–2748 PubMedPubMedCentralCrossRef Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133(9):2734–2748 PubMedPubMedCentralCrossRef
Zurück zum Zitat Jeffery OJ, Lennon VA, Pittock SJ, Gregory JK, Britton JW, McKeon A (2013) GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 81:882–887 PubMedPubMedCentralCrossRef Jeffery OJ, Lennon VA, Pittock SJ, Gregory JK, Britton JW, McKeon A (2013) GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 81:882–887 PubMedPubMedCentralCrossRef
Zurück zum Zitat Johnson N, Henry C, Fessler AJ, Dalmau J (2010) Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 75(16):1480–1482 PubMedPubMedCentralCrossRef Johnson N, Henry C, Fessler AJ, Dalmau J (2010) Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 75(16):1480–1482 PubMedPubMedCentralCrossRef
Zurück zum Zitat Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9(1):67–76 PubMedCrossRef Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9(1):67–76 PubMedCrossRef
Zurück zum Zitat Leypoldt F, Armangue T, Dalmau J (2015) Autoimmune encephalopathies. Ann N Y Acad Sci 1338:94–114 PubMedCrossRef Leypoldt F, Armangue T, Dalmau J (2015) Autoimmune encephalopathies. Ann N Y Acad Sci 1338:94–114 PubMedCrossRef
Zurück zum Zitat Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, Baruzzi A, Carey T, Gambetti P, Lugaresi E, Montagna P (2001) Morvan’s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124(Pt 12):2417–2426 PubMedCrossRef Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, Baruzzi A, Carey T, Gambetti P, Lugaresi E, Montagna P (2001) Morvan’s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124(Pt 12):2417–2426 PubMedCrossRef
Zurück zum Zitat Linke R, Schroeder M, Helmberger T, Voltz R (2004) Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 63(2):282–286 PubMedCrossRef Linke R, Schroeder M, Helmberger T, Voltz R (2004) Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 63(2):282–286 PubMedCrossRef
Zurück zum Zitat Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67(4):470–478 PubMedCrossRef Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67(4):470–478 PubMedCrossRef
Zurück zum Zitat Mantegazza R, Bernasconi P, Baggi F, Spreafico R, Ragona F, Antozzi C, Bernardi G, Granata T (2002) Antibodies against GluR3 peptides are not specific for Rasmussen’s encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 131(1–2):179–185 PubMedCrossRef Mantegazza R, Bernasconi P, Baggi F, Spreafico R, Ragona F, Antozzi C, Bernardi G, Granata T (2002) Antibodies against GluR3 peptides are not specific for Rasmussen’s encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 131(1–2):179–185 PubMedCrossRef
Zurück zum Zitat Martinez-Hernandez E, Arino H, McKeon A, Iizuka T, Titulaer MJ, Simabukuro MM et al (2016) Clinical and immunologic investigations in patients with Stiff-Person spectrum disorder. JAMA Neurol 73:714–720 PubMedPubMedCentralCrossRef Martinez-Hernandez E, Arino H, McKeon A, Iizuka T, Titulaer MJ, Simabukuro MM et al (2016) Clinical and immunologic investigations in patients with Stiff-Person spectrum disorder. JAMA Neurol 73:714–720 PubMedPubMedCentralCrossRef
Zurück zum Zitat Matà S, Muscas GC, Naldi I, Rosati E, Paladini S, Cruciatti B, Bisulli F, Paganini M, Mazzi G, Sorbi S, Tinuper PJ (2008) Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. Neuroimmunol 199(1–2):155–159 CrossRef Matà S, Muscas GC, Naldi I, Rosati E, Paladini S, Cruciatti B, Bisulli F, Paganini M, Mazzi G, Sorbi S, Tinuper PJ (2008) Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. Neuroimmunol 199(1–2):155–159 CrossRef
Zurück zum Zitat Mori M, Kuwabara S, Yoshiyama M, Kanesaka T, Ogata T, Hattori T (2002) Successful immune treatment for non-paraneoplastic limbic encephalitis. J Neurol Sci 201(1–2):85–88 PubMedCrossRef Mori M, Kuwabara S, Yoshiyama M, Kanesaka T, Ogata T, Hattori T (2002) Successful immune treatment for non-paraneoplastic limbic encephalitis. J Neurol Sci 201(1–2):85–88 PubMedCrossRef
Zurück zum Zitat Oguni H, Andermann F, Rasmussen TB (1992) The syndrome of chronic encephalitis and epilepsy. A study based on the MNI series of 48 cases. Adv Neurol 57:419–433 PubMed Oguni H, Andermann F, Rasmussen TB (1992) The syndrome of chronic encephalitis and epilepsy. A study based on the MNI series of 48 cases. Adv Neurol 57:419–433 PubMed
Zurück zum Zitat Quartuccio N, Caobelli F, Evangelista L, Alongi P, Kirienko M, De BV et al (2015) The role of PET/CT in the evaluation of patients affected by limbic encephalitis: a systematic review of the literature. J Neuroimmunol 284:44–48 PubMedCrossRef Quartuccio N, Caobelli F, Evangelista L, Alongi P, Kirienko M, De BV et al (2015) The role of PET/CT in the evaluation of patients affected by limbic encephalitis: a systematic review of the literature. J Neuroimmunol 284:44–48 PubMedCrossRef
Zurück zum Zitat Sansing LH, Tüzün E, Ko MW, Baccon J, Lynch DR, Dalmau J (2007) A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 3(5):291–296 PubMedPubMedCentralCrossRef Sansing LH, Tüzün E, Ko MW, Baccon J, Lynch DR, Dalmau J (2007) A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 3(5):291–296 PubMedPubMedCentralCrossRef
Zurück zum Zitat Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D (2012) Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79:1094–1100 PubMedPubMedCentralCrossRef Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D (2012) Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79:1094–1100 PubMedPubMedCentralCrossRef
Zurück zum Zitat Sonderen A van, Arino H, Petit-Pedrol M, Leypoldt F, Kortvelyessy P, Wandinger KP et al (2016) The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87(5):521–528 PubMedPubMedCentralCrossRef Sonderen A van, Arino H, Petit-Pedrol M, Leypoldt F, Kortvelyessy P, Wandinger KP et al (2016) The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87(5):521–528 PubMedPubMedCentralCrossRef
Zurück zum Zitat Tobias SM, Robitaille Y, Hickey WF, Rhodes CH, Nordgren R, Andermann F (2003) Bilateral Rasmussen encephalitis: postmortem documentation in a five-year-old. Epilepsia 44(1):127–130 PubMedCrossRef Tobias SM, Robitaille Y, Hickey WF, Rhodes CH, Nordgren R, Andermann F (2003) Bilateral Rasmussen encephalitis: postmortem documentation in a five-year-old. Epilepsia 44(1):127–130 PubMedCrossRef
Zurück zum Zitat Urbach H, Sassen R, Soeder BM, Flacke S, Becker A, Bien CG (2006a) Serial MRI in patients with aquired hippocampal sclerosis. Clin Neuroradiol 16:47–52 CrossRef Urbach H, Sassen R, Soeder BM, Flacke S, Becker A, Bien CG (2006a) Serial MRI in patients with aquired hippocampal sclerosis. Clin Neuroradiol 16:47–52 CrossRef
Zurück zum Zitat Urbach H, Soeder BM, Jeub M, Klockgether T, Meyer B, Bien CG (2006b) Serial MRI of limbic encephalitis. Neuroradiology 48(6):380–386 PubMedCrossRef Urbach H, Soeder BM, Jeub M, Klockgether T, Meyer B, Bien CG (2006b) Serial MRI of limbic encephalitis. Neuroradiology 48(6):380–386 PubMedCrossRef
Zurück zum Zitat Villani F, Pincherle A, Antozzi C, Chiapparini L, Granata T, Michelucci R, Rubboli G, Simone I, Bellomo R, Spreafico R (2006) Adult-onset Rasmussen’s encephalitis: anatomical-electrographic-clinical features of 7 Italian cases. Epilepsia 47(Suppl 5):41–46 PubMedCrossRef Villani F, Pincherle A, Antozzi C, Chiapparini L, Granata T, Michelucci R, Rubboli G, Simone I, Bellomo R, Spreafico R (2006) Adult-onset Rasmussen’s encephalitis: anatomical-electrographic-clinical features of 7 Italian cases. Epilepsia 47(Suppl 5):41–46 PubMedCrossRef
Zurück zum Zitat Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127(Pt 3):701–712 PubMedCrossRef Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127(Pt 3):701–712 PubMedCrossRef
Zurück zum Zitat Watson R, Jiang Y, Bermudez I, Houlihan L, Clover L, McKnight K, Cross JH, Hart IK, Roubertie A, Valmier J, Hart Y, Palace J, Beeson D, Vincent A, Lang B (2004) Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 63(1):43–50 PubMedCrossRef Watson R, Jiang Y, Bermudez I, Houlihan L, Clover L, McKnight K, Cross JH, Hart IK, Roubertie A, Valmier J, Hart Y, Palace J, Beeson D, Vincent A, Lang B (2004) Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 63(1):43–50 PubMedCrossRef
Zurück zum Zitat Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, Ternamian PJ, Trouillas P, Honnorat J (2004) FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 127(Pt 10):2331–2338 PubMedCrossRef Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, Ternamian PJ, Trouillas P, Honnorat J (2004) FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 127(Pt 10):2331–2338 PubMedCrossRef
Zurück zum Zitat Zuliani L, Saiz A, Tavolato B, Giometto B, Vincent A, Graus F (2007) Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumour. J Neurol Neurosurg Psychiatry 78(2):204–205 PubMedPubMedCentralCrossRef Zuliani L, Saiz A, Tavolato B, Giometto B, Vincent A, Graus F (2007) Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumour. J Neurol Neurosurg Psychiatry 78(2):204–205 PubMedPubMedCentralCrossRef
Metadaten
Titel
Multiple Sklerose und andere autoimmune ZNS-Erkrankungen
verfasst von
Martin Stangel
Christoph Kleinschnitz
Mathias Mäurer
Peter Raab
Kurt-Wolfram Sühs
Corinna Trebst
Copyright-Jahr
2018
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-55530-9_1